Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Alvine

Orthopaedic Surgery of the Spine Sioux Falls, SD Medical Doctor

NPI 1861452500 CMS profile 758293

810 E 23Rd St, Sioux Falls, SD 57105

Open in the dashboard

General payments

$3,147

29 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Alvine of Sioux Falls, SD is reported in the CMS Open Payments database as having received $3,147 across 29 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $436 4
2024 General $111 1
2023 General $149 3
2022 General $262 2
2021 General $1,315 4
2020 General $142 2
2019 General $733 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Alvine
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Gregory Alvine were reported at $436. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Gregory Alvine Orthopaedic Surgery of the Spine median Middle half National median
2019 $733 $2,106 $337–$18,608 $163
2020 $142 $1,213 $156–$15,082 $114
2021 $1,315 $1,834 $271–$15,617 $132
2022 $262 $2,015 $320–$17,036 $149
2023 $149 $1,925 $336–$14,599 $160
2024 $111 $2,110 $341–$12,483 $164
2025 $436 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Conetic Solutions, Inc. $1,200 1 payment
  2. Medtronic USA, Inc. $466 7 payments
  3. Stryker Corporation $457 3 payments
  4. Wright Medical Technology, Inc. $409 8 payments
  5. Medtronic, Inc. $242 3 payments
  6. Bioventus LLC $123 1 payment
  7. DePuy Synthes Sales Inc. $95 2 payments
  8. Cerapedics, Inc. $92 1 payment
  9. Globus Medical, Inc. $48 2 payments
  10. Abbott Laboratories $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,799 27 payments
  2. Education $1,200 1 payment
  3. Travel and Lodging $147 1 payment
Products named General payments · program years 2019–2025
  1. INFINITY $409 8 payments
  2. KYPHON Balloon Kyphoplasty $274 5 payments
  3. UNID_PASS $213 2 payments
  4. INBONE $212 1 payment
  5. AUGMENT INJECTABLE $159 1 payment
  6. ALLOPURE $159 1 payment
  7. CLAW II $159 1 payment
  8. EXOGEN ULTRASOUND BONE HEALING SYSTEM $123 1 payment
  9. nanoLOCK-C $108 1 payment
  10. I-FACTOR PEPTIDE ENHANCED BONE GRAFT $92 1 payment
  11. Other $357 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

511

Median for Orthopedic Surgery: 203

Drug cost

$3,264

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 149 $1,233
Celecoxib Generic 28 $853
Cyclobenzaprine Hcl Generic 35 $551
Meloxicam Generic 102 $199
Methylprednisolone Generic 35 $197
Cephalexin Generic 14 $84
Tramadol Hcl Generic 25 $57
Amoxicillin Generic 81 $53
Alprazolam Generic 29 $19
Clindamycin Hcl Generic 13 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 127 billing codes

Paid by Medicare

$222,721

Of which drugs: $167

Medicare patients

647

Average age 73

Services billed

2,213

368 women, 279 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 27%
Ischemic heart disease 27%
Depression 21%
Chronic kidney disease 20%
Osteoporosis 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 27 31 $148

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

29 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record